Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
MRNA · against 43 other Healthcare companies of similar size
Ranked #43 of 44 · scores higher than 0% of peers
Bars: peers in each 10-point band of the valuation score2 peers with a valuation score of 0–9, including MRNA · Click a bar to see the companies
Mainly because of its EBITDA yield and earnings yield, which are weaker than most Healthcare peers.
| Metric | MRNA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 42 reported | -3.5% | 3.2% | 0% | 30% | |
| EBITDA yieldHigher is better · 45 reported | -2.5% | 6.5% | 0% | 50% | |
| Free cash flow yieldHigher is better · 34 reported | -1.4% | 3.9% | 0% | 20% | |
| Book yieldHigher is better · 41 reported | 7.4% | 19.7% | 15% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 177.5B USD | 92 | 71 | |
| 2 | 78.1B USD | 89 | 60 | |
| 3 | 108.6B USD | 88 | 66 | |
| 4 | 97.5B USD | 87 | 67 | |
| 5 | 45.9B USD | 84 | 61 | |
| 38 | 155.7B USD | 47 | 64 | |
| 40 | 49.1B USD | 46 | 69 | |
| 41 | 66.3B USD | 44 | 30 | |
| 42 | 56.7B USD | 42 | 79 | |
| 43 | 91.2B USD | 8 | 18 | |
| 43 | 56.0B USD | 8 | 39 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score